Abstract
Tumour cell expression of the PD-L1 may allow it to evade T-cell mediated killing, and therefore plays an important role in cancer progression. The clinical efficacy of PD-1/PD-L1 inhibitor therapy in non-small cell lung cancer (NSCLC) patients is greatest in high PD-L1 expressing tumours. Additionally, pembrolizumab (anti-PD-1; Keynote-189) and atezolizumab (anti-PD-L1; Impower130 Trial) combined with chemotherapy has also demonstrated greater clinical efficacy than chemotherapy alone, even in patients with low-PD-L1 tumours.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
